Despite the potential, targeting p53 in cancer therapy presents several challenges. The heterogeneity of p53 mutations means that a one-size-fits-all approach is unlikely to be effective. Additionally, the potential for adverse effects on normal cells, which also depend on p53 for genomic integrity, must be carefully managed. Researchers are continually working to develop more selective and effective therapies.
